Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics' Total Non-Current Liabilities history spans 7 years, with the latest figure at $13.8 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 42.73% to $13.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.8 million, a 42.73% increase, with the full-year FY2025 number at $13.8 million, up 42.73% from a year prior.
  • Total Non-Current Liabilities hit $13.8 million in Q4 2025 for Insight Molecular Diagnostics, up from $9.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for IMDX hit a ceiling of $87.3 million in Q4 2021 and a floor of $8.5 million in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $26.9 million across 5 years, with a median of $14.1 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 489.13% in 2021 and later plummeted 81.34% in 2023.
  • Tracing IMDX's Total Non-Current Liabilities over 5 years: stood at $87.3 million in 2021, then plummeted by 79.5% to $17.9 million in 2022, then crashed by 49.0% to $9.1 million in 2023, then grew by 5.7% to $9.6 million in 2024, then skyrocketed by 42.73% to $13.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for IMDX at $13.8 million in Q4 2025, $9.2 million in Q3 2025, and $8.5 million in Q2 2025.